Tel:
Fax:
Email:
Creative Biolabs

NeuroMab™ Anti-CD133 BBB Shuttle Antibody(NRZP-1022-ZP3393)

[CAT#: NRZP-1022-ZP3393]

Host Species:
Mouse
Species Reactivity:
Human; Mouse; Rat
Applications:
FC; Cyt; ADCC; In Vitro

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Species Reactivity

Human; Mouse; Rat

Clonality

Monoclonal

Host Species

Mouse

Applications

FC; Cyt; ADCC; In Vitro

Relevant Diseases

Glioma
Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only
Target

Target

CD133

Official Name

PROM1

Full Name

CD133 antigen

Alternative Names

PROM1; AC133; CD133; CORD12; MCDR2; MSTP061; PROML1; RP41; STGD4; prominin 1
Product Pictures
FuncS

Figure 1 shows the effect of Fc-optimized chimeric antibodies chim293AClC3B9-SDIE (A) and chimW6B3H10-SDIE (B) and unstimulated human PBMC on cultured CD 133 expressing human WERI- Cell killing effect of Rbl cells and chimW6B3H10.

FuncS

Figure 2 shows the cell killing effect of a chimeric antibody against NG2, which has been Fc-optimized at the same position as the above antibody, on human SKMel63-melanoma cells. Cytotoxicity was determined using a chromium release assay, indicating the duration of the assay and the target-effector ratio.

FCM

Figure 3 shows the binding of the CD133 antibody 293C3 (293AC1C3B9) to PBMCs of nine chronic lymphocytic leukemia (CLL) patients, as determined by flow cytometry.

Publications

Publications (0)

gift-card

Related Products
For Research Use Only. Not For Clinical Use.
Product
Hot Products
Fill out this form for a quote Inquiry Form Send Inquiry
webinar

The Spectrum of Stem Cell-Based Neuronal Models and Their Fit for Purpose

2:00 PM–3:00 PM EST, December 12, 2024

REGISTER NOW
Inquiry Basket
compare

Send inquiry